Atara Biotherapeutics, Inc
ATRA
ATRA: Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
moreShow ATRA Financials
Recent trades of ATRA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ATRA's directors and management
Government lobbying spending instances
-
$60,000 Jul 13, 2023 Issue: Health Issues
-
$60,000 Apr 07, 2023 Issue: Health Issues
-
$60,000 Jan 18, 2023 Issue: Health Issues
-
$60,000 Oct 11, 2022 Issue: Health Issues
-
$60,000 Jul 20, 2022 Issue: Health Issues
-
$60,000 Apr 20, 2022 Issue: Health Issues
-
$60,000 Jan 09, 2022 Issue: Health Issues
-
$60,000 Oct 14, 2021 Issue: Health Issues
-
$60,000 Jul 19, 2021 Issue: Health Issues
-
$40,000 Apr 19, 2021 Issue: Health Issues
New patents grants
-
Patent Title: Administration of an anti-activin-a compound to a subject Jan. 03, 2023
-
Patent Title: Variant activin receptor polypeptides and uses thereof Aug. 06, 2013
-
Patent Title: Stabilized activin iib receptor polypeptides and uses thereof Apr. 02, 2013
Federal grants, loans, and purchases
Followers on ATRA's company Twitter account
Number of mentions of ATRA in WallStreetBets Daily Discussion
Recent insights relating to ATRA
Recent picks made for ATRA stock on CNBC
ETFs with the largest estimated holdings in ATRA
Flights by private jets registered to ATRA